XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

The 8-year overall survival rate was 78.9% with enzalutamide-leuprolide and 69.5% with leuprolide alone. Treatment with enzalutamide plus leuprolide reduces the risk of death by more than 40% in ...

Differences in Patient-Reported Outcome Measures in Patients With Cancer Six Months Before Death All premenopausal patients who underwent first HSCT from June 2016 to January 2022 were included in ...

Based on EMBARK data, both enzalutamide monotherapy and combination therapy (with leuprolide) reduced the likelihood of distant metastasis in patients with high-risk biochemically recurrent prostate ...

LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...

The proportion of patients with serum luteinizing hormone (LH) suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimulation test at Week 24 was 94%, and the results were statistically ...

Lupron Depot (leuprolide) has potential interactions with other medications and some supplements. These interactions could affect how well the drug works or cause harmful effects. Lupron Depot is used ...